Physician

Frank David Newby, M.D., PH. D

According to 2025 Medicare claims, Frank Newby, M.D., PH. D (NPI: 1801889696) practices nephrology in the Dalton, GA market, with the plurality of this provider's patient population coming from Whitfield, GA. This provider's primary affiliated billing organization is NEPHROLOGY & HYPERTENSION SPECIALISTS PC (NPI: 1720295561; TIN: 581597233) and primary practice location at 30720-3011.

Newby's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 506 traditional Medicare patients, billed 4,918 HCPCS/CPT codes, and received $241,782 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,784 prescription claims across 434 beneficiaries totaling $489,427 in drug costs, led by Xphozah (Tenapanor Hcl). DME data shows 125 claims. Open Payments data shows 92 records totaling $1,724. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $438,580 to $241,782. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $683,077 to $489,427. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $605 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	973	14,475	$438,580
2016	974	17,142	$499,998
2017	1,050	15,121	$498,751
2018	946	14,074	$442,443
2019	930	12,946	$385,770
2020	690	7,871	$263,321
2021	760	8,601	$326,905
2022	622	6,960	$285,135
2023	698	8,289	$302,636
2024	506	4,918	$241,782

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	538	6,825	$683,077
2016	533	7,067	$784,497
2017	564	6,624	$929,610
2018	465	4,866	$581,745
2019	413	3,385	$462,635
2020	374	3,186	$492,760
2021	338	2,823	$374,804
2022	334	2,473	$300,831
2023	413	2,632	$336,220
2024	434	2,784	$489,427

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	22	311	$16,496
2016	N/R	380	$21,164
2017	N/R	390	$17,328
2018	N/R	249	$10,637
2019	N/R	159	$4,321
2020	N/R	286	$7,574
2021	N/R	150	$4,782
2022	N/R	111	$2,668
2023	N/R	194	$6,288
2024	N/R	125	$3,877

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	255	384	$84
80069	Kidney function blood test panel	224	340	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	239	378	$8
36415	Insertion of needle into vein for collection of blood sample	254	447	$7
81003	Automated urinalysis test	261	386	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xphozah	Tenapanor Hcl	64	2,040	$196,823
Rayaldee	Calcifediol	76	2,280	$93,138
Farxiga	Dapagliflozin Propanediol	51	2,700	$50,513
Kerendia	Finerenone	53	1,950	$41,187
Nifedipine Er	Nifedipine	90	4,570	$1,707

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	28	$2,678
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	38	$439
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	23	$414
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	18	$333
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	18	$14

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	92	$1,724	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Frank David Newby, M.D., PH. D?

Tedicare shows public-source Medicare data for Frank David Newby, M.D., PH. D (NPI 1801889696), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Frank David Newby, M.D., PH. D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Frank David Newby, M.D., PH. D?

Frank David Newby, M.D., PH. D is linked to NEPHROLOGY & HYPERTENSION SPECIALISTS PC (billing NPI 1720295561) in the available physician profile data.

Does Frank David Newby, M.D., PH. D have Open Payments data?

Frank David Newby, M.D., PH. D has 92 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.